Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health, Inc. (symbol: GH) is a pioneering biotechnology company headquartered in Redwood City, California. The company specializes in liquid-based cancer tests, providing innovative diagnostic tools for both clinical and research purposes. Guardant Health is renowned for its comprehensive liquid biopsy solutions, which offer non-invasive methods to access and sequence tumor DNA.
The company's flagship products include:
- Guardant360 LDT: A liquid biopsy test that assists in treatment selection for advanced-stage cancer patients.
- Guardant360 CDx: An FDA-approved companion diagnostic for several targeted therapies, ensuring precise treatment plans.
- Guardant OMNI: A broad gene panel designed for immuno-oncology research, aiding in the understanding of cancer's genetic underpinnings.
- Reveal: Launched in 2021, this tumor-agnostic molecular residual disease (MRD) test helps monitor cancer recurrence or residual disease at the molecular level.
- Shield: Introduced in 2022, this lab-developed test offers a non-invasive screening option for colorectal cancer (CRC).
Guardant Health's cutting-edge technologies have been widely adopted by thousands of oncologists globally, benefiting tens of thousands of advanced cancer patients. The company has made significant strides in early cancer detection, with ongoing projects that promise to deliver profound impacts on patient care.
Financially, Guardant Health has raised over $500 million from prestigious investors such as Sequoia Capital, Khosla Ventures, Orbimed, and SoftBank. This substantial backing underscores the confidence in Guardant's potential to revolutionize cancer diagnostics and treatment.
In addition to its product offerings, Guardant Health provides research development services, including regulatory approval consultancy and clinical trial referrals. These services are designed to support the seamless integration of their diagnostic tools into clinical practice and research settings.
Stay updated with the latest news and developments about Guardant Health, Inc. as the company continues to push the boundaries of cancer diagnostics and treatment.
Guardant Health (GH) reported third quarter 2021 revenue of $94.8 million, a 27% increase from the prior year. Clinical testing revenue grew 35% with 22,806 tests performed, while biopharmaceutical tests rose 58% to 4,839. The gross profit reached $64 million, with a gross margin of 67%, though operating expenses rose 34% to $171.3 million, leading to a net loss of $107.5 million. Full-year revenue guidance is projected between $360 million and $370 million.
Guardant Health (GH) has partnered with The Royal Marsden NHS Foundation Trust to establish an in-house liquid biopsy testing service, enhancing cancer diagnostics in the UK. This facility, set to operationalize by the end of 2022, will enable rapid and precise diagnostic testing for late-stage cancer patients. Guardant Health’s liquid biopsy tests are pivotal in guiding treatment decisions and facilitating clinical trials. With 375,000 new cancer cases reported in the UK from 2016-2018, this collaboration aims to improve patient outcomes through personalized treatment approaches.
Guardant Health's LUNAR-2 blood test shows promising results for colorectal cancer screening, achieving 96% sensitivity and 94% specificity in a study presented at the American College of Gastroenterology Annual Scientific Meeting.
Conducted on a cohort of 699 patients, the test particularly excels in detecting early-stage cancers, reaching 93% sensitivity for Stage 1 and 2 CRC. A larger trial, ECLIPSE, is underway to further validate these findings. Guardant aims to provide a non-invasive, easy-to-use alternative for CRC screening, potentially improving patient outcomes amidst declining screening rates.
Guardant Health (Nasdaq: GH) has appointed Myrtle Potter to its Board of Directors. This decision aims to enhance the company's mission in precision oncology.
Co-CEO Helmy Eltoukhy expressed confidence in Potter's extensive industry experience and product development expertise. Myrtle Potter, currently CEO of Sumitovant Biopharma, brings significant experience from her previous roles at Genentech and Bristol-Myers Squibb. Her appointment comes at a crucial time for Guardant Health, which focuses on innovative oncology products and aims to improve patient access to these advancements.
Guardant Health, Inc. (NASDAQ: GH) will announce its third-quarter financial results on November 4, 2021, post-market. A conference call will follow at 1:30 PM PT / 4:30 PM ET, available via webcast on the company's website. Guardant Health specializes in precision oncology, providing proprietary tests like Guardant360 and Guardant Reveal to enhance cancer care and improve patient outcomes. These tests are integral to their comprehensive oncology platform aimed at reducing healthcare costs and supporting advanced and early-stage cancer patients.
Guardant Health has launched the ORACLE study, a 1,000-patient, multi-center trial aimed at assessing the Guardant Reveal™ test's ability to predict cancer recurrence in 11 solid tumor types. The study will monitor circulating tumor DNA (ctDNA) levels for up to five years. This blood-only liquid biopsy test is designed to improve decision-making for oncologists treating early-stage cancer by identifying patients at risk for recurrence. Guardant Health intends to extend the application of this test beyond colorectal cancer, showcasing its commitment to enhancing patient care.
Guardant Health presented critical findings at the ESMO 2021 congress, revealing the need for improved HER2-directed therapies in metastatic colorectal cancer. Their Guardant360® liquid biopsy test highlighted treatment resistance patterns and molecular targets essential for personalized cancer care. Key studies emphasized the unmet need for effective treatments for HER2+ mCRC patients and provided insights into molecular features in early-onset colorectal cancer. The data underscores the importance of liquid biopsy in enhancing clinical outcomes for advanced cancer patients.
Guardant Health (Nasdaq: GH) will present new data on its Guardant360 liquid biopsy test at the IASLC 2021 World Conference on Lung Cancer, highlighting its advantages in clinical decision-making for advanced lung cancer. The data aims to demonstrate the test's ability to rapidly identify actionable biomarkers, facilitating quicker treatment initiation compared to traditional tissue biopsies. Key presentations include studies on genomic profiling and treatment impact, scheduled from September 8-14, 2021.
Guardant Health, a precision oncology leader, will participate virtually in the Morgan Stanley Global Healthcare Conference on September 9, 2021, at 1:15 p.m. PT. Interested individuals can access a live and archived webcast via the company’s website. Guardant Health focuses on cancer care through advanced tests like Guardant360 and Guardant Reveal, aiming to improve patient outcomes and reduce healthcare costs. The company is dedicated to enhancing cancer screening, particularly for asymptomatic individuals.
Guardant Health, a leader in precision oncology, announced its participation in the UBS Genomics 2.0 and MedTech Innovations Summit on August 10 at 4:00 p.m. PT. The event will feature a fireside chat with the company’s management, accessible via a webcast on their website. Guardant Health specializes in revolutionary cancer testing technologies like Guardant360 and Guardant Reveal, aimed at improving clinical outcomes and reducing costs. Their innovations support comprehensive cancer care and screening programs to help combat cancer globally.
FAQ
What is the current stock price of Guardant Health (GH)?
What is the market cap of Guardant Health (GH)?
What does Guardant Health, Inc. specialize in?
What are the main products offered by Guardant Health?
What is Guardant360 CDx?
How does Guardant Health support cancer research?
What is the significance of the Reveal test?
What is the purpose of the Shield test?
Who are some of the major investors in Guardant Health?
Where is Guardant Health, Inc. headquartered?
What is the Guardant360 LDT test used for?
How does Guardant Health contribute to early cancer detection?
